ACETAMINOPHEN: POTENTIAL PEDIATRIC HAZARD

PEDIATRICS ◽  
1973 ◽  
Vol 52 (6) ◽  
pp. 883-883
Author(s):  
C. F. W.

Acetaminophen, long popular in Europe, has received increasing use in the United States as an analgesic and antipyretic, in both adult and pediatric practice. This increased use has come about partly because of concern over side effects of aspirin, especially its interference with blood-clotting mechanisms. Pediatric use of acetaminophen has been facilitated because it can be formulated into a stable suspension, easy to administer to children. Acetaminophen is available in many forms and formulations, alone and in combination, in both prescription and over-the-counter products. The table at the end of this section, admittedly incomplete, lists some 200 brand names of products containing this compound which are marketed in the United States. The extensive availability of acetaminophen increases the probability of accidental ingestion of toxic quantities by infants and children. Although package inserts characterize this drug as having exceptional safety in recommended doses, ingestion of moderately large quantities can cause kidney and liver damage resulting sometimes in death. Adverse side effects have been reported from lesser quantities. It is, therefore, important to alert practitioners to the potential toxicity, symptomatology and procedures for handling overdose. A highly significant aspect in such incidents is that early signs of poisoning may be minimal, even in cases where death ultimately occurs. Unaware of this, a physician might delay intensive therapy. Poisoning by acetaminophen and its treatment have been extensively studied in the United Kingdom where consumption of this drug has progressively risen over the past decade and has been accompanied by an increasing number of poisonings.

2020 ◽  
Vol 25 (1) ◽  
pp. 1-15 ◽  
Author(s):  
Amaia Del Campo ◽  
Marisalva Fávero

Abstract. During the last decades, several studies have been conducted on the effectiveness of sexual abuse prevention programs implemented in different countries. In this article, we present a review of 70 studies (1981–2017) evaluating prevention programs, conducted mostly in the United States and Canada, although with a considerable presence also in other countries, such as New Zealand and the United Kingdom. The results of these studies, in general, are very promising and encourage us to continue this type of intervention, almost unanimously confirming its effectiveness. Prevention programs encourage children and adolescents to report the abuse experienced and they may help to reduce the trauma of sexual abuse if there are victims among the participants. We also found that some evaluations have not considered the possible negative effects of this type of programs in the event that they are applied inappropriately. Finally, we present some methodological considerations as critical analysis to this type of evaluations.


2020 ◽  
Vol 119 (820) ◽  
pp. 303-309
Author(s):  
J. Nicholas Ziegler

Comparing the virus responses in Germany, the United Kingdom, and the United States shows that in order for scientific expertise to result in effective policy, rational political leadership is required. Each of these three countries is known for advanced biomedical research, yet their experiences in the COVID-19 pandemic diverged widely. Germany’s political leadership carefully followed scientific advice and organized public–private partnerships to scale up testing, resulting in relatively low infection levels. The UK and US political responses were far more erratic and less informed by scientific advice—and proved much less effective.


2020 ◽  
pp. 1-24
Author(s):  
Rehana Cassim

Abstract Section 162 of the South African Companies Act 71 of 2008 empowers courts to declare directors delinquent and hence to disqualify them from office. This article compares the judicial disqualification of directors under this section with the equivalent provisions in the United Kingdom, Australia and the United States of America, which have all influenced the South African act. The article compares the classes of persons who have locus standi to apply to court to disqualify a director from holding office, as well as the grounds for the judicial disqualification of a director, the duration of the disqualification, the application of a prescription period and the discretion conferred on courts to disqualify directors from office. It contends that, in empowering courts to disqualify directors from holding office, section 162 of the South African Companies Act goes too far in certain respects.


Sign in / Sign up

Export Citation Format

Share Document